Neoadjuvant therapy for pancreatic cancer
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …
surgical resection of the primary tumour and systemic chemotherapy, which provides …
Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches
Cancer is one of the leading causes of death worldwide. Several treatments are available for
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …
Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology
MA Tempero, MP Malafa, M Al-Hawary… - Journal of the National …, 2021 - jnccn.org
Pancreatic cancer is the fourth leading cause of cancer-related death among men and
women in the United States. A major challenge in treatment remains patients' advanced …
women in the United States. A major challenge in treatment remains patients' advanced …
Therapeutic developments in pancreatic cancer: current and future perspectives
The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Neoadjuvant chemotherapy can improve the survival of individuals with borderline and
unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to …
unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to …
[HTML][HTML] Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre …
JP Neoptolemos, DH Palmer, P Ghaneh, EE Psarelli… - The Lancet, 2017 - thelancet.com
Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in …
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in …
Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features
Background & Aims Genomic studies have revealed subtypes of pancreatic ductal
adenocarcinoma (PDA) based on their molecular features, but different studies have …
adenocarcinoma (PDA) based on their molecular features, but different studies have …
Pancreatic cancer chemoresistance to gemcitabine
M Amrutkar, IP Gladhaug - Cancers, 2017 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …
ranks among the leading causes of cancer-related deaths in the Western world due to …
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Ducreux, AS Cuhna, C Caramella… - Annals of …, 2015 - annalsofoncology.org
A recent study estimating cancer epidemiology in 2014 (within Europe) showed that
pancreatic cancer was the fourth most fatal cancer in men after lung, colorectal, and prostate …
pancreatic cancer was the fourth most fatal cancer in men after lung, colorectal, and prostate …
Chemotherapy for pancreatic cancer
C Springfeld, D Jäger, MW Büchler, O Strobel… - La Presse Medicale, 2019 - Elsevier
Chemotherapy is an important part of multimodality pancreatic cancer treatment. After
curative resection, adjuvant chemotherapy can significantly improve disease free survival …
curative resection, adjuvant chemotherapy can significantly improve disease free survival …